HK1028401A1 - A process for the reduction of oxiranyl epothilones to olefinic epothilones - Google Patents

A process for the reduction of oxiranyl epothilones to olefinic epothilones

Info

Publication number
HK1028401A1
HK1028401A1 HK00107869A HK00107869A HK1028401A1 HK 1028401 A1 HK1028401 A1 HK 1028401A1 HK 00107869 A HK00107869 A HK 00107869A HK 00107869 A HK00107869 A HK 00107869A HK 1028401 A1 HK1028401 A1 HK 1028401A1
Authority
HK
Hong Kong
Prior art keywords
epothilones
reduction
oxiranyl
olefinic
relates
Prior art date
Application number
HK00107869A
Other languages
English (en)
Inventor
Soong-Hoon Kim
James A Johnson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1028401A1 publication Critical patent/HK1028401A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK00107869A 1997-12-04 2000-12-07 A process for the reduction of oxiranyl epothilones to olefinic epothilones HK1028401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6754997P 1997-12-04 1997-12-04
US8256398P 1998-04-21 1998-04-21
PCT/US1998/025464 WO1999028324A1 (en) 1997-12-04 1998-12-01 A process for the reduction of oxiranyl epothilones to olefinic epothilones

Publications (1)

Publication Number Publication Date
HK1028401A1 true HK1028401A1 (en) 2001-02-16

Family

ID=26748002

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00107869A HK1028401A1 (en) 1997-12-04 2000-12-07 A process for the reduction of oxiranyl epothilones to olefinic epothilones

Country Status (13)

Country Link
EP (1) EP1042327B1 (es)
JP (1) JP4434484B2 (es)
KR (1) KR100574454B1 (es)
AT (1) ATE250066T1 (es)
AU (1) AU738576B2 (es)
CA (1) CA2311929A1 (es)
DE (1) DE69818304T2 (es)
ES (1) ES2207015T3 (es)
HK (1) HK1028401A1 (es)
HU (1) HUP0100582A3 (es)
IL (1) IL135590A (es)
TW (1) TWI221469B (es)
WO (1) WO1999028324A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0977563B1 (en) 1996-12-03 2005-10-12 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
JP2002504540A (ja) * 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
KR20050043796A (ko) * 2002-05-20 2005-05-11 코산 바이오사이언시즈, 인코포레이티드 에포틸론 ｄ의 투여방법
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003302084A1 (en) 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
GB0405898D0 (en) * 2004-03-16 2004-04-21 Novartis Ag Organic compounds
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
EP2665493B1 (en) 2011-01-20 2018-03-21 Board Of Regents, The University Of Texas System Mri markers, delivery and extraction systems, and methods of manufacture and use thereof
MX368966B (es) 2011-06-10 2019-10-23 Mersana Therapeutics Inc Conjugados de proteina-polimero-farmaco.
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
TN2015000543A1 (en) 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
JP6427564B2 (ja) 2013-10-11 2018-11-21 アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー タンパク質−ポリマー−薬物共役体
EP3054991B1 (en) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN103936748A (zh) * 2014-05-08 2014-07-23 成都摩尔生物医药有限公司 一种埃博霉素b内酰胺衍生物的制备方法
EP3474901A1 (en) 2016-06-27 2019-05-01 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3641826B1 (en) 2017-06-22 2023-12-06 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
US20210308207A1 (en) 2018-05-04 2021-10-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
EA202191175A1 (ru) 2018-10-29 2021-09-08 Мерсана Терапьютикс, Инк. Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
US20230121556A1 (en) 2019-06-17 2023-04-20 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
CA3230774A1 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
EP4186529A1 (en) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
WO2023158305A1 (en) 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) * 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59609305D1 (de) * 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung

Also Published As

Publication number Publication date
DE69818304T2 (de) 2004-07-01
DE69818304D1 (de) 2003-10-23
JP2001525324A (ja) 2001-12-11
KR20010031976A (ko) 2001-04-16
AU738576B2 (en) 2001-09-20
HUP0100582A3 (en) 2003-03-28
ES2207015T3 (es) 2004-05-16
EP1042327A4 (en) 2002-07-17
KR100574454B1 (ko) 2006-04-27
WO1999028324A1 (en) 1999-06-10
EP1042327A1 (en) 2000-10-11
IL135590A (en) 2003-09-17
IL135590A0 (en) 2001-05-20
HUP0100582A2 (hu) 2001-09-28
AU1540899A (en) 1999-06-16
CA2311929A1 (en) 1999-06-10
JP4434484B2 (ja) 2010-03-17
TWI221469B (en) 2004-10-01
ATE250066T1 (de) 2003-10-15
EP1042327B1 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
HK1028401A1 (en) A process for the reduction of oxiranyl epothilones to olefinic epothilones
HUP0201467A2 (en) A process for the reduction of oxiranyl epothilones to olefinic epothilones
AU1601100A (en) Improved processes for the synthesis of oligomeric compounds
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
HUP0103946A2 (hu) Eljárás olefinek előállítására
BG102788A (en) New methods for the preparation of intermediate compounds for presticides
IL133363A (en) Process for the production of herapin
BG103649A (en) Method for the preparation of eprosartan
BG103650A (en) Method for the preparation of eprosartan
HK1032047A1 (en) Process for the synthesis of hiv protease inhibitors
IL123014A0 (en) Process for the production of halogeno-o-hydroxydiphenyl compounds
IL128028A0 (en) Treatment of psychotic disorders
EP0617040A3 (en) Production of alkyl phosphites.
ZA989338B (en) Process for the synthesis of chloropurine intermediates.
GB2327420B (en) Process for the production of oxygenated compounds
IL124178A (en) Process for the production of distryryl-biphenyl compounds
HUP9900493A3 (en) General process for the epoxidation of olefinic double bonds
MX9603450A (es) Procedimiento para la obtencion de aminotriazolinas substituidas.
AU2460995A (en) Production of olefins by transhydrogenation
BG102563A (en) Method and intermediate compounds for the production of pesticidal fluorolefinic compounds
AU5477199A (en) Novel process for the synthesis of exochelins
AU6302698A (en) Process for the purification of substituted p-nitrodiphenylethers
AU1063300A (en) Process for the production of trifluoromethyltropanone cyanohydrin
HK1034064A1 (en) Process for the production of formylimidazoles
AU7969600A (en) Process for the partial hydrogenation of a nitrile compound containing two or more nitrile groups

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081201